Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 30;11:4413–4429. doi: 10.2147/OTT.S162255

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Xue et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Zyflamend showed synergistic anticancer effect with cisplatin on UBC cells.

Notes: (A and B) Cell viability of UBC cells treated with Zyflamend (50 μg/mL) and/or cisplatin (1 μg/mL) for 72 h detected by MTT assay. Viability of vehicle treated cells was defined as 100%. (C and D) Chou-Talalay method FA-CI plots to assess drug synergy between Zyflamend and cisplatin against T24R (C) and J82 cells (D). CI values less than 1.0 indicate synergism of the two agents. (E) Colony-formation capability of UBC cells treated with Zyflamend and cisplatin individually or combined for 7 days. (F and G) Quantification of colony numbers under the treatment of Zyflamend and cisplatin, individually or combined. Data are presented as mean ± SE; ***P<0.001.

Abbreviations: UBC, urinary bladder cancer; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CI, combination index; T24R, cisplatin-resistant T24 cell; SE, standard error; FA, fraction affected.

Zyflamend showed synergistic anticancer effect with cisplatin on UBC cells.

Notes: (A and B) Cell viability of UBC cells treated with Zyflamend (50 μg/mL) and/or cisplatin (1 μg/mL) for 72 h detected by MTT assay. Viability of vehicle treated cells was defined as 100%. (C and D) Chou-Talalay method FA-CI plots to assess drug synergy between Zyflamend and cisplatin against T24R (C) and J82 cells (D). CI values less than 1.0 indicate synergism of the two agents. (E) Colony-formation capability of UBC cells treated with Zyflamend and cisplatin individually or combined for 7 days. (F and G) Quantification of colony numbers under the treatment of Zyflamend and cisplatin, individually or combined. Data are presented as mean ± SE; ***P<0.001.

Abbreviations: UBC, urinary bladder cancer; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CI, combination index; T24R, cisplatin-resistant T24 cell; SE, standard error; FA, fraction affected.